Novartis AG operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Novartis with three other
pharmaceutical manufacturers in Europe:
Bayer AG
of GERMANY
(2020
sales of 41.40 billion Euros [US$48.94 billion]
of which 46%
was CropScience),
Sanofi S.A.
of FRANCE
(37.37 billion Euros [US$44.17 billion]
of which 69%
was Pharmaceuticals), and
GlaxoSmithKline plc
which is
based in UNITED KINGDOM
(£34.10 billion [US$47.16 billion]
of which 50%
was Pharmaceuticals).
Sales Analysis.
During the second
quarter of 2021, sales at Novartis totalled
12.13 billion Swiss Francs.
This is
an increase of 11.8%
from the 10.85 billion Swiss Francs in sales at the company during the second quarter of 2020.
This was the biggest same quarter rise in sales at Novartis in the previous 35 quarters.
During the first two
quarters of 2021, sales totalled 23.73 billion Swiss Francs, which is
4.5% higher
than through the first two quarters of 2020.
Novartis reported sales of 46.58 billion Swiss Francs (US$50.63 billion)
for the
year ending
December of 2020.
This
represents
a
decrease of 3.6%
versus 2019, when the company's sales were 48.29 billion Swiss Francs.
The sales level in 2020 was fairly close to the level five years ago: in 2015, Novartis had sales
of 48.55 billion Swiss Francs.
Contributing to the drop in overall sales was the 6.8% decline
in Sandoz, from 9.66 billion Swiss Francs to 9.00 billion Swiss Francs.
There were also decreases in sales in
Innovative Medicines (down 3.3% to 36.42 billion Swiss Francs)
.